Literature DB >> 34297835

Comparison between robot-assisted thoracoscopic surgery and video-assisted thoracoscopic surgery for mediastinal and hilar lymph node dissection in lung cancer surgery.

Tomohiro Haruki1, Yuzo Takagi1, Yasuaki Kubouchi1, Yoshiteru Kidokoro1, Atsuyuki Nakanishi1, Yuji Nozaka1, Yuki Oshima1, Shinji Matsui1, Hiroshige Nakamura1.   

Abstract

OBJECTIVES: Lymph node dissection (LND) with robot-assisted thoracoscopic surgery (RATS) in lung cancer surgery has not been fully evaluated. The aim of this study was to compare LND surgical results between video-assisted thoracoscopic surgery (VATS) and RATS.
METHODS: We retrospectively compared perioperative parameters, including the incidence of LND-associated complications (chylothorax, recurrent and/or phrenic nerve paralysis and bronchopleural fistula), lymph node (LN) counts and postoperative locoregional recurrence, among 390 patients with primary lung cancer who underwent lobectomy and mediastinal LND by RATS (n = 104) or VATS (n = 286) at our institution.
RESULTS: The median total dissected LN numbers significantly differed between the RATS and the VATS groups (RATS: 18, VATS: 15; P < 0.001). They also significantly differed in right upper zone and hilar (#2R + #4R + #10L) (RATS: 12, VATS: 10; P = 0.002), left lower paratracheal and hilar (#4L + #10L) (RATS: 4, VATS: 3; P = 0.019), aortopulmonary zone (#5 + #6) (RATS: 3, VATS: 2; P = 0.001) and interlobar and lobar (#11 + #12) LNs (RATS: 7, VATS: 6; P = 0.041). The groups did not significantly differ in overall nodal upstaging (P = 0.64), total blood loss (P = 0.69) or incidence of LND-associated complications (P = 0.77).
CONCLUSIONS: In this comparison, it was suggested that more LNs could be dissected using RATS than VATS, especially in bilateral superior mediastinum and hilar regions. Accumulation of more cases and longer observation periods are needed to verify whether RATS can provide the acceptable quality of LND and local control of lung cancer.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  LND-associated complication; Lung cancer; Lymph node dissection; Nodal upstaging; Robot-assisted thoracoscopic surgery; Video-assisted thoracoscopic surgery

Mesh:

Year:  2021        PMID: 34297835      PMCID: PMC8691695          DOI: 10.1093/icvts/ivab112

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  28 in total

1.  The association of nodal upstaging with surgical approach and its impact on long-term survival after resection of non-small-cell lung cancer.

Authors:  Mark W Hennon; Luke H DeGraaff; Adrienne Groman; Todd L Demmy; Sai Yendamuri
Journal:  Eur J Cardiothorac Surg       Date:  2020-05-01       Impact factor: 4.191

2.  Initial Results of Robotic Surgery for Primary Lung Cancer: Feasibility, Safety and Learning Curve.

Authors:  Yuji Taniguchi; Hiroshige Nakamura; Ken Miwa; Tomohiro Haruki; Kunio Araki; Yuzo Takagi; Makoto Wakahara; Yohei Yurugi; Yasuaki Kubouchi; Takashi Ohno; Yoshiteru Kidokoro; Wakako Fujiwara
Journal:  Yonago Acta Med       Date:  2017-09-15       Impact factor: 1.641

3.  Nodal Upstaging in Robotic and Video Assisted Thoracic Surgery Lobectomy for Clinical N0 Lung Cancer.

Authors:  Benjamin E Lee; Mark Shapiro; John R Rutledge; Robert J Korst
Journal:  Ann Thorac Surg       Date:  2015-05-30       Impact factor: 4.330

Review 4.  Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Di Meng; Zhenyu Zhou; Yiqing Wang; Luming Wang; Wang Lv; Jian Hu
Journal:  Eur J Cardiothorac Surg       Date:  2016-04-22       Impact factor: 4.191

5.  Efficacy of lymph node dissection during robotic-assisted lobectomy for non-small cell lung cancer: retrospective review of 159 consecutive cases.

Authors:  Frank O Velez-Cubian; Kathryn L Rodriguez; Matthew R Thau; Carla C Moodie; Joseph R Garrett; Jacques P Fontaine; Eric M Toloza
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

6.  Comparison of systematic mediastinal lymph node dissection versus systematic sampling for lung cancer staging and completeness of surgery.

Authors:  Nan Wu; Shi Yan; Chao Lv; Yuan Feng; Yuzhao Wang; Lijian Zhang; Yue Yang
Journal:  J Surg Res       Date:  2011-05-20       Impact factor: 2.192

7.  Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter.

Authors:  K Sugi; K Nawata; N Fujita; K Ueda; T Tanaka; T Matsuoka; Y Kaneda; K Esato
Journal:  World J Surg       Date:  1998-03       Impact factor: 3.352

8.  Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group.

Authors:  S M Keller; S Adak; H Wagner; D H Johnson
Journal:  Ann Thorac Surg       Date:  2000-08       Impact factor: 4.330

9.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.

Authors:  Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03       Impact factor: 5.209

10.  Distribution and Prevalence of Locoregional Recurrence after Video-Assisted Thoracoscopic Surgery for Primary Lung Cancer.

Authors:  Tomohiro Haruki; Ken Miwa; Kunio Araki; Yuji Taniguchi; Hiroshige Nakamura
Journal:  Thorac Cardiovasc Surg       Date:  2015-08-10       Impact factor: 1.827

View more
  1 in total

1.  Propensity score-matched comparison of robotic- and video-assisted thoracoscopic surgery, and open lobectomy for non-small cell lung cancer patients aged 75 years or older.

Authors:  Hanbo Pan; Zenan Gu; Yu Tian; Long Jiang; Hongda Zhu; Junwei Ning; Jia Huang; Qingquan Luo
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.